BioXcel Therapeutics (BTAI) Cash from Financing Activities (2017 - 2026)

BioXcel Therapeutics' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $232000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 98.24% year-over-year to $232000.0; the TTM figure through Mar 2026 stood at $43.5 million (up 87.42% YoY), while the FY2025 annual figure was $56.5 million, up 54.17% from the prior year.
• Cash from Financing Activities was $232000.0 for Q1 2026 at BioXcel Therapeutics, down from $5.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $37.5 million in Q3 2025 to a low of $50000.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $10.7 million across 5 years, with a median of $4.8 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities soared 42221.13% in 2022, then plunged 98.24% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $50000.0 in 2022, then surged by 4146.0% to $2.1 million in 2023, then surged by 101.41% to $4.3 million in 2024, then soared by 32.06% to $5.6 million in 2025, then slumped by 95.89% to $232000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $232000.0 (Q1 2026), $5.6 million (Q4 2025), and $37.5 million (Q3 2025), per Business Quant data.